Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | $210.78M |
| Net Income (Most Recent Fiscal Year) | $65.63M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 8.09 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.44 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 4.13 |
| Pre-Tax Margin (Trailing 12 Months) | 13.82% |
| Net Margin (Trailing 12 Months) | 14.39% |
| Return on Equity (Trailing 12 Months) | 5.84% |
| Return on Assets (Trailing 12 Months) | 4.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 21.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 21.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.42 |
| Earnings per Share (Most Recent Fiscal Year) | $1.68 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.95M |
| Free Float | 35.07M |
| Market Capitalization | $248.60M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | -0.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.59% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |